US biotechnology company Vir Biotechnology rises as much as 22 percent in US premarket trading after the company’s Phase 3 Eclipse 1 study achieved all primary and key secondary endpoints. This is stated in a press release.
The study evaluates the drug combination of elebsiran and tobevibart for the treatment of chronic hepatitis D.
The results show that 44 percent of the patients who received the combination treatment had undetectable viral levels and normalized liver values after 48 weeks, compared with zero percent in the delayed-treatment group at week 12. Furthermore, 79 percent of the treated patients achieved undetectable viral levels, compared with zero percent in the comparator group.
The study included 124 patients and also showed positive results in patients with liver cirrhosis. The treatment was generally well tolerated, with one more serious treatment-related adverse event and no treatment discontinuations.
